首页> 外文期刊>The Journal of Steroid Biochemistry and Molecular Biology >Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors.
【24h】

Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors.

机译:非甾体雌酮硫酸酯酶抑制剂的合成和硫酸酯酶抑制活性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

About one-third of breast cancers are classified as estrogen-dependent breast cancers. In the past 10 years, numerous reports have suggested the importance of estrone sulfate and estrone sulfatase in regulating the supply of estrogens to these cancers. Estrone sulfatase inhibitors may thus prove to be useful for the treatment of these diseases. Several research groups have reported the development of estrone sulfatase inhibitors, and estrone-3-O-sulfamate has been shown to be the most potent sulfatase inhibitor. However, a recent report indicated that estrone may be released during the inactivation of sulfatase by estrone-3-O-sulfamate and rendered the inhibitor to be estrogenic. Therefore, there is a need for a potent non-steroidal sulfatase inhibitor that is metabolically stable, more selective, and lacking estrogenic activity. We developed a series of (p-O-sulfamoyl)-N-alkanoyl tyramines, and they proved to be potent estrone sulfatase inhibitors. Using human placental microsome as the enzyme source,the best inhibitor in this series, compound 18, has an IC50 of 55.8 nM. Another potent inhibitor in this series, compound 17, exhibited time-dependent inactivation of sulfatase when incubated at various concentrations (0.2-1.0 microM) of the inhibitor. Estrone sulfate partially blocked the inactivation of the enzyme by the compound, indicating that the compound inactivated sulfatase at the active site. The irreversible nature of the enzyme-inhibitor interaction was supported by irreversibility studies. Thus, (p-O-sulfamoyl)-N-alkanoyl tyramines represent a new series of non-steroidal estrone sulfatase inhibitor.
机译:大约三分之一的乳腺癌被归类为雌激素依赖性乳腺癌。在过去的十年中,大量报告表明硫酸雌酮和硫酸雌酮硫酸酯酶在调节这些癌症中雌激素的供应中的重要性。因此,证明雌酮硫酸酯酶抑制剂可用于治疗这些疾病。几个研究小组已经报告了雌酮硫酸酯酶抑制剂的开发,并且雌酮-3-O-氨基磺酸酯已被证明是最有效的硫酸酯酶抑制剂。然而,最近的报道表明,雌酮-3-O-氨基磺酸酯使硫酸酯酶失活期间可能释放出雌酮,并使该抑制剂具有雌激素作用。因此,需要有效的非甾体硫酸酯酶抑制剂,其代谢稳定,更具选择性且缺乏雌激素活性。我们开发了一系列(p-O-氨磺酰基)-N-烷酰基酪胺,它们被证明是有效的雌酮硫酸酯酶抑制剂。使用人胎盘微粒体作为酶源,该系列中最好的抑制剂化合物18的IC50为55.8 nM。当在各种浓度(0.2-1.0 microM)的抑制剂中孵育时,该系列中的另一种有效抑制剂化合物17会显示出硫酸酯酶的时间依赖性灭活。硫酸雌酮部分阻止了该化合物对酶的灭活,表明该化合物在活性位点灭活了硫酸酯酶。酶-抑制剂相互作用的不可逆性得到不可逆性研究的支持。因此,(对-O-氨磺酰基)-N-烷酰基酪胺代表了一系列新的非甾体雌酮硫酸酯酶抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号